Swedish Orphan Revenue vs. Price To Sales

B6E Stock  EUR 26.44  0.04  0.15%   
Considering Swedish Orphan's profitability and operating efficiency indicators, Swedish Orphan Biovitrum may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Swedish Orphan's ability to earn profits and add value for shareholders.
For Swedish Orphan profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Swedish Orphan to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Swedish Orphan Biovitrum utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Swedish Orphan's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Swedish Orphan Biovitrum over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Swedish Orphan's value and its price as these two are different measures arrived at by different means. Investors typically determine if Swedish Orphan is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Swedish Orphan's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Swedish Orphan Biovitrum Price To Sales vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Swedish Orphan's current stock value. Our valuation model uses many indicators to compare Swedish Orphan value to that of its competitors to determine the firm's financial worth.
Swedish Orphan Biovitrum is rated below average in revenue category among its peers. It is rated third in price to sales category among its peers . The ratio of Revenue to Price To Sales for Swedish Orphan Biovitrum is about  4,239,884,235 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Swedish Orphan's earnings, one of the primary drivers of an investment's value.

Swedish Revenue vs. Competition

Swedish Orphan Biovitrum is rated below average in revenue category among its peers. Market size based on revenue of Drug Manufacturers - Specialty & Generic industry is currently estimated at about 4.94 Trillion. Swedish Orphan adds roughly 15.53 Billion in revenue claiming only tiny portion of equities under Drug Manufacturers - Specialty & Generic industry.

Swedish Price To Sales vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Swedish Orphan

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
15.53 B
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Swedish Orphan

P/S

 = 

MV Per Share

Revenue Per Share

 = 
3.66 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Swedish Price To Sales Comparison

Swedish Orphan is rated second in price to sales category among its peers.

Swedish Orphan Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Swedish Orphan, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Swedish Orphan will eventually generate negative long term returns. The profitability progress is the general direction of Swedish Orphan's change in net profit over the period of time. It can combine multiple indicators of Swedish Orphan, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. SWEDISH ORPHAN is traded on Frankfurt Stock Exchange in Germany.

Swedish Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Swedish Orphan. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Swedish Orphan position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Swedish Orphan's important profitability drivers and their relationship over time.

Use Swedish Orphan in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Swedish Orphan position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Swedish Orphan will appreciate offsetting losses from the drop in the long position's value.

Swedish Orphan Pair Trading

Swedish Orphan Biovitrum Pair Trading Analysis

The ability to find closely correlated positions to Swedish Orphan could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Swedish Orphan when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Swedish Orphan - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Swedish Orphan Biovitrum to buy it.
The correlation of Swedish Orphan is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Swedish Orphan moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Swedish Orphan Biovitrum moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Swedish Orphan can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Swedish Orphan position

In addition to having Swedish Orphan in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Oil And Gas Thematic Idea Now

Oil And Gas
Oil And Gas Theme
Companies involved in drilling, production, and distribution of oil and gas pipelines. The Oil And Gas theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Oil And Gas Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Swedish Stock

To fully project Swedish Orphan's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Swedish Orphan Biovitrum at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Swedish Orphan's income statement, its balance sheet, and the statement of cash flows.
Potential Swedish Orphan investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Swedish Orphan investors may work on each financial statement separately, they are all related. The changes in Swedish Orphan's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Swedish Orphan's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.